Phase 2 Myelosuppression Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 2
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
NSCLC (Advanced Non-small Cell Lung Cancer)EGFRMyelosuppression
The First Affiliated Hospital of Xiamen University49 enrolled1 locationNCT06992739
Recruiting
Phase 2
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Thoracic NeoplasmsChemoradiotherapyMyelosuppression
Affiliated Hospital of Nantong University30 enrolled1 locationNCT07205536
Recruiting
Phase 2
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
Non-small Cell Lung CancerMyelosuppression
The First Affiliated Hospital of Xiamen University33 enrolled1 locationNCT06929936
Recruiting
Phase 2
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Ewing SarcomaMyelosuppression
Fudan University22 enrolled1 locationNCT06699472
Recruiting
Phase 2
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Myelosuppression
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT06490081